What is the Purpose of this Study?
This study focuses on people who have been diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle thickens and blocks blood flow from the heart. The purpose of the study is to evaluate the effect of a drug called mavacamten on the size, weight, and thickness of the two left chambers (atrium and ventricle) of the heart, in addition to assessing the safety and tolerability of mavacamten in patients with oHCM. Study procedures also include echocardiograms, electrocardiograms, blood draws, and questionnaires. Mavacamten may help the heart muscle to relax, reducing contraction and improving heart function in oHCM. It is approved the U.S. Food and Drug Administration (FDA) to treat patients with oHCM to improve heart function and reduce the symptoms of oHCM.
Eligibility
- * Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:.
- * Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
- * Left ventricular ejection fraction (LVEF) ≥ 55% at rest.
- * New York Heart Association (NYHA) functional class II or III symptoms.
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging